Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. MicroPort Scientific Corporation
  6. Summary
    853   KYG608371046

MICROPORT SCIENTIFIC CORPORATION

(853)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
01/10/2022 01/11/2022 01/12/2022 01/13/2022 01/14/2022 Date
26.6 27.9 28.75 27.5 27.95 Last
5456315 12355970 8748583 4689006 2664710 Volume
+5.98% +4.89% +3.05% -4.35% +1.64% Change
Estimated financial data (e) (USD)
Sales 2021 778 M - -
Net income 2021 -179 M - -
Net cash position 2021 912 M - -
P/E ratio 2021 -37,8x
Yield 2021 0,09%
Sales 2022 957 M - -
Net income 2022 -111 M - -
Net cash position 2022 639 M - -
P/E ratio 2022 -58,8x
Yield 2022 0,07%
Capitalization 6 442 M 6 442 M -
EV / Sales 2021 7,11x
EV / Sales 2022 6,06x
Nbr of Employees 8 303
Free-Float 47,2%
More Financials
Company
MicroPort Scientific Corporation is a Hong Kong-based investment holding company principally engaged in the manufacture and sales of medical products. The Company operates through seven segments. Orthopedics Devices segment researches, develops, manufactures and sells orthopedics devices. Cardiovascular Devices segment researches, develops, manufactures and sells cardiovascular devices, such as drug eluting stents.... 
More about the company
Ratings of MicroPort Scientific Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about MICROPORT SCIENTIFIC CORPORATION
01/13MICROPORT SCIENTIFIC : « CRM Receives Approval in Japan for Alizea™ Bluetooth« Pacem..
PU
01/07MICROPORT SCIENTIFIC : Results of Pre-Market Clinical Trial “CATCH” for MicroP..
PU
2021MICROPORT SCIENTIFIC : Endovastec™ Receives Approval for Hercules™-LP Stent Gr..
PU
2021MICROPORT SCIENTIFIC : « MedBot« Toumai« Mobile Showing & Training Center Launched
PU
2021MicroPort Scientific's Neurovascular Business Files for Hong Kong IPO; Shares Slide 5%
MT
2021MICROPORT SCIENTIFIC : « MedBot« Conducts Animal Testing Using Unmanned, Fully Automated S..
PU
2021MICROPORT SCIENTIFIC : « Firehawk« Stent System Approved for Marketing in Australia
PU
2021MICROPORT SCIENTIFIC : « CRM Receives CE Mark Approval for NAVIGO™ Left Ventricular ..
PU
2021MICROPORT SCIENTIFIC : «'s Four Sports Medicine Products Approved for Marketing
PU
2021MICROPORT SCIENTIFIC : Fontus™ System of Endovastec™ Approved for Marketing by..
PU
2021MICROPORT SCIENTIFIC : NeuroTech™ Bridge« Vertebral Drug-Eluting Stent Presents in F..
PU
2021MICROPORT SCIENTIFIC : « MedBot« Completes the First Enrollment in Toumai« Single-Arm Surg..
PU
2021MICROPORT SCIENTIFIC : « Orthopedics Celebrates First Hip Replacement Surgery in Brazil Us..
PU
2021MICROPORT SCIENTIFIC : Article on Clinical Use of Endovastec™ Castor™ Stent Fi..
PU
2021MICROPORT SCIENTIFIC : « MedBot« Announces the Completion of the First Confirmatory Clinic..
PU
More news
News in other languages on MICROPORT SCIENTIFIC CORPORATION
2021L'activité neurovasculaire de MicroPort Scientific fait l'objet d'une introduction en b..
2021MicroPort MedBot lève 29 millions de dollars grâce à l'exercice intégral de l'option de..
2021L'unité neurovasculaire de MicroPort Scientific lève 150 millions de dollars dans le ca..
2021MicroPort Scientific octroie près de 2 millions d'options sur actions à ses employés
2021MicroPort Scientific fixe les droits des actionnaires dans le cadre de l'essaimage du b..
More news
Chart MICROPORT SCIENTIFIC CORPORATION
Duration : Period :
MicroPort Scientific Corporation Technical Analysis Chart | 853 | KYG608371046 | MarketScreener
Technical analysis trends MICROPORT SCIENTIFIC CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 3,59 $
Average target price 6,59 $
Spread / Average Target 83,7%
EPS Revisions
Managers and Directors
Zhao Hua Chang Chairman & Chief Executive Officer
Hong Bin Sun Chief Financial Officer
Qi Yi Luo Chief Technology Officer
Glendy Wang Chief Operating Officer
Jonathan H. Chou Independent Non-Executive Director
Sector and Competitors